India Proposes Classifying Manipulated Cells And Tissue Products As Drugs
The Indian government is proposing to change the definition of a new drug to include substantially manipulated stem cell and tissue-based therapies.
You may also be interested in...
Draft update to national guidelines factors in additional safeguards and makes it mandatory to establish institutional panels to review stem cell research. Gene editing would be an area of "restrictive" research.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
The European pharmaceutical industry federation, EFPIA, says its member companies are not looking for shortcuts to develop and validate digital biomarkers, but want help from regulators to create the right evidence.